Table 4. CIN Positivity and Clinicopathological AJCC Staging of Cancer Cohorts.

	BRAF mut/MSS (Serrated)	P value	BRAF wt/MSS (Traditional)	P value	P value between cohorts
Overall CIN+ | AJCC Stage:
Stage I	1/2 (50.0%)	0.046	8/11 (72.7%)	0.41	1.0
Stage II	5/11 (45.5%)		23/26 (88.5%)		0.01
Stage III	9/11 (81.8%)		15/20 (75%)		1.0
Stage IV	6/6 (100%)		12/13 (92.3%)		1.0
Stages I + II/CIN+	6/13 (46.2%)	0.02	31/37 (83.8%)	1.0	0.02
Stages III + IV/CIN	15/17 (88.2%)		27/33 (81.8%)		0.70
5q CIN+ and Stage:
Stage I	0/1 (0%)	0.16	5/8 (62.5%)	0.95	0.44
Stage II	2/12 (16.7%)		14/25 (56.0%)		0.04
Stage III	3/11 (27.3%)		9/17 (52.9%)		0.25
Stage IV	3/4 (75.0%)		8/13 (61.5%)		1.0
Stages I + II	2/13 (15.4%)	0.22	19/33 (57.6%)	1.0	0.02
Stages III + IV	6/15 (40.0%)		17/30 (56.7%)		0.35
8p CIN+ and Stage:
Stage I	1/1 (100%)	0.37	3/9 (33.3%)	0.47	0.40
Stage II	2/5 (40.0%)		12/18 (66.7%)		0.34
Stage III	4/9 (44.4%)		10/18 (55.6%)		0.70
Stage IV	5/6 (83.3%)		6/11 (54.5%)		0.33
Stages I + II	3/6 (50.0%)	1.0	15/27 (55.6%)	1.0	1.0
Stages III + IV	9/15 (60.0%)		16/29 (55.2%)		1.0
17p CIN+ and Stage:
Stage I	0/2 (0%)	0.052	4/6 (66.7%)	0.94	0.43
Stage II	2/6 (33.3%)		16/23 (69.6%)		0.16
Stage III	4/8 (50.0%)		10/13 (76.9%)		0.35
Stage IV	5/5 (100%)		6/9 (66.7%)		0.26
Stages I + II	2/8 (25.0%)	0.08	20/29 (69.0%)	1.0	0.04
Stages III + IV	9/13 (69.2%)		16/22 (72.7%)		1.0
18q CIN+ and Stage:
Stage I	1/2 (50.0%)	0.09	7/11 (63.6%)	0.87	1.0
Stage II	1/9 (11.1%)		15/22 (68.2%)		0.006
Stage III	6/9 (66.7%)		10/18 (55.6%)		0.69
Stage IV	3/5 (60.0%)		8/13 (61.5%)		1.0
Stages I + II	2/11 (18.2%)	0.04	22/33 (66.7%)	0.61	0.01
Stages III + IV	9/14 (64.3%)		18/31 (58.1%)		0.75
Overall CIN+|TNM Stage:
T1	0	0.83	3/5 (60.0%)	0.59	–
T2	2/3 (66.7%)		6/7 (85.7%)		1.0
T3	13/20 (65.0%)		39/47 (82.0%)		0.12
T4	6/7 (85.7%)		8/9 (88.9%)		1.0
N0	6/13 (46.2%)	0.07	36/42 (85.7%)	0.58	0.007
N1	7/8 (87.5%)		14/18 (77.8%)		1.0
N2	8/9 (88.9%)		7/9 (77.8%)		1.0
M0	11/17 (64.7%)	0.14	44/55 (80.0%)	0.44	0.263
M1	6/6 (100%)		12/13 (92.3%)		1.0